Kusurinomadoguchi (5592) investor relations material

Executive summary

• All business segments achieved year-over-year revenue and profit growth, resulting in record-high consolidated sales and operating profit for Q1 FY2026.

• Revenue for Q1 FY2026 was ¥2,914 million, up 10.8% year-over-year, with operating profit at ¥629 million, up 64.5% year-over-year, and net income attributable to shareholders at ¥387 million, up 61.4% year-over-year.

• Growth was driven by increased prescription reservations in the media business, higher pharmaceutical distribution in "Minna no Okusuribako," and enhanced data integration in core systems.

• Cost optimization, including subsidiary rationalization, contributed to improved profitability.

Financial highlights

• Consolidated revenue: ¥2,914 million, up 11% year-over-year; operating profit: ¥629 million, up 65% year-over-year; net income attributable to shareholders: ¥387 million, up 61.4% year-over-year.

• EBITDA: ¥975 million, up 46% year-over-year.

• Gross profit: ¥1,688 million, up 10% year-over-year.

• Comprehensive income for Q1 FY2026 was ¥411 million, up 82.5% year-over-year.

• EPS for Q1 FY2026 was ¥33.98, compared to ¥21.28 in the prior year.

Outlook and guidance

• Full-year FY2026 guidance maintained: revenue ¥12,300 million (+12.6% YoY), operating profit ¥2,200 million (+10.0% YoY), net income attributable to shareholders ¥2,240 million (+10.1% YoY), EPS ¥199.59.

• No change to full-year guidance; deferred tax asset from capital reduction to be recognized in Q2, supporting net income progress.

• Q1 progress rates: operating profit at 28.6% of full-year target, ordinary profit at 30.2%, net income at 17.2% due to deferred tax asset adjustments expected in Q2.